JP2024508088A5 - - Google Patents

Info

Publication number
JP2024508088A5
JP2024508088A5 JP2023541092A JP2023541092A JP2024508088A5 JP 2024508088 A5 JP2024508088 A5 JP 2024508088A5 JP 2023541092 A JP2023541092 A JP 2023541092A JP 2023541092 A JP2023541092 A JP 2023541092A JP 2024508088 A5 JP2024508088 A5 JP 2024508088A5
Authority
JP
Japan
Prior art keywords
hsv
oncolytic
glycoprotein
passage
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023541092A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024508088A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/015703 external-priority patent/WO2022173767A1/en
Publication of JP2024508088A publication Critical patent/JP2024508088A/ja
Publication of JP2024508088A5 publication Critical patent/JP2024508088A5/ja
Pending legal-status Critical Current

Links

JP2023541092A 2021-02-09 2022-02-08 全身送達及び抗腫瘍活性の向上のための腫瘍溶解性ウイルス Pending JP2024508088A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163200011P 2021-02-09 2021-02-09
US63/200,011 2021-02-09
US202163263528P 2021-11-04 2021-11-04
US63/263,528 2021-11-04
PCT/US2022/015703 WO2022173767A1 (en) 2021-02-09 2022-02-08 Oncolytic virus for systemic delivery and enhanced anti-tumor activities

Publications (2)

Publication Number Publication Date
JP2024508088A JP2024508088A (ja) 2024-02-22
JP2024508088A5 true JP2024508088A5 (cg-RX-API-DMAC7.html) 2025-02-18

Family

ID=80623426

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023541092A Pending JP2024508088A (ja) 2021-02-09 2022-02-08 全身送達及び抗腫瘍活性の向上のための腫瘍溶解性ウイルス

Country Status (6)

Country Link
US (1) US20240123004A1 (cg-RX-API-DMAC7.html)
EP (1) EP4291216A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024508088A (cg-RX-API-DMAC7.html)
AU (1) AU2022219921A1 (cg-RX-API-DMAC7.html)
CA (1) CA3202849A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022173767A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230295661A1 (en) * 2022-03-16 2023-09-21 University Of Houston System Persistent hsv gene delivery system

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8200523A (nl) 1982-02-11 1983-09-01 Univ Leiden Werkwijze voor het in vitro transformeren van planteprotoplasten met plasmide-dna.
US4879236A (en) 1984-05-16 1989-11-07 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
EP0273085A1 (en) 1986-12-29 1988-07-06 IntraCel Corporation A method for internalizing nucleic acids into eukaryotic cells
US4952500A (en) 1988-02-01 1990-08-28 University Of Georgia Research Foundation, Inc. Cloning systems for Rhodococcus and related bacteria
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5302523A (en) 1989-06-21 1994-04-12 Zeneca Limited Transformation of plant cells
US5550318A (en) 1990-04-17 1996-08-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US7705215B1 (en) 1990-04-17 2010-04-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5322783A (en) 1989-10-17 1994-06-21 Pioneer Hi-Bred International, Inc. Soybean transformation by microparticle bombardment
US5484956A (en) 1990-01-22 1996-01-16 Dekalb Genetics Corporation Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5610042A (en) 1991-10-07 1997-03-11 Ciba-Geigy Corporation Methods for stable transformation of wheat
DK0604662T3 (da) 1992-07-07 2008-10-20 Japan Tobacco Inc Fremgangsmåde til transformering af monocotyledon
US5702932A (en) 1992-07-20 1997-12-30 University Of Florida Microinjection methods to transform arthropods with exogenous DNA
AU670316B2 (en) 1992-07-27 1996-07-11 Pioneer Hi-Bred International, Inc. An improved method of (agrobacterium)-mediated transformation of cultured soybean cells
DE4228457A1 (de) 1992-08-27 1994-04-28 Beiersdorf Ag Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen
GB9222888D0 (en) 1992-10-30 1992-12-16 British Tech Group Tomography
US5656610A (en) 1994-06-21 1997-08-12 University Of Southern California Producing a protein in a mammal by injection of a DNA-sequence into the tongue
FR2722208B1 (fr) 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
US5871986A (en) 1994-09-23 1999-02-16 The General Hospital Corporation Use of a baculovirus to express and exogenous gene in a mammalian cell
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
US5945100A (en) 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
US5981274A (en) 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors
US6013265A (en) 1996-10-22 2000-01-11 University Of Maryland, Baltimore Vaccine composition for herpes simplex virus and methods of using
US5994624A (en) 1997-10-20 1999-11-30 Cotton Incorporated In planta method for the production of transgenic plants
US8986672B2 (en) * 2005-06-23 2015-03-24 The University Of Houston Use of mutant Herpes Simplex Virus-2 for cancer therapy
US20150246086A1 (en) 2005-06-23 2015-09-03 The University Of Houston System Use of Mutant Herpes Simplex Virus-2 for Cancer Therapy
WO2012071276A1 (en) 2010-11-23 2012-05-31 Xiaoliu Zhang Oncolytic virus as an inducer for innate antitumor immunity
EP3400291B2 (en) * 2016-01-08 2024-02-28 Replimune Limited Engineered virus
ES2976558T3 (es) * 2017-06-21 2024-08-05 The Board Of Trustees Of The Leland Stanfordjunior Univ Parámetros de dosificación para terapias de direccionamiento de CD47 en neoplasias hematológicas
CN112368007A (zh) * 2018-05-31 2021-02-12 高等教育联邦系统-匹兹堡大学 抗原隐匿的溶瘤病毒

Similar Documents

Publication Publication Date Title
Mal et al. Inactivation of p27Kip1 by the viral E1A oncoprotein in TGFβ-treated cells
Cui et al. Rabbits immunized with Epstein-Barr virus gH/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350
Diefenbach et al. Herpes simplex virus tegument protein US11 interacts with conventional kinesin heavy chain
Johnson et al. Differential mechanisms of complement-mediated neutralization of the closely related paramyxoviruses simian virus 5 and mumps virus
Rowe et al. Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes
Rux et al. Kinetic analysis of glycoprotein C of herpes simplex virus types 1 and 2 binding to heparin, heparan sulfate, and complement component C3b
CA2475604C (en) An herpes simplex virus complex
Hung et al. The interaction of glycoprotein C of herpes simplex virus types 1 and 2 with the alternative complement pathway
WO2022089471A1 (zh) 一种β冠状病毒多聚体抗原、其制备方法和应用
Modrow et al. Characterization of two related Epstein-Barr virus-encoded membrane proteins that are differentially expressed in Burkitt lymphoma and in vitro-transformed cell lines.
JP2001509373A5 (cg-RX-API-DMAC7.html)
CA2177699A1 (en) Vector, viral protein, nucleotide sequence coding therefor and method for inhibiting immune recognition
US20140227281A1 (en) Methods of Treating Herpesvirus Infections
WO2019044926A1 (ja) 抗HSV gBモノクローナル抗体又はその抗原結合断片
KITAY et al. Protein–protein interactions between Epstein–Barr virus nuclear antigen-LP and cellular gene products: binding of 70-kilodalton heat shock proteins
Pratt et al. Enhanced expression of the Marek's disease virus-specific phosphoproteins after stable transfection of MSB-1 cells with the Marek's disease virus homologue of ICP4
WO2019018796A1 (en) VACCINE EPITOPES AGAINST HERPES SIMPLEX VIRUS RECOGNIZED SPECIFICALLY BY MEMORY T LYMPHOCYTES RESIDING IN FABRICS
Haarr et al. Utilization of internal AUG codons for initiation of protein synthesis directed by mRNAs from normal and mutant genes encoding herpes simplex virus-specified thymidine kinase
US12258408B2 (en) Oncolytic virus expressing PD-1 binding protein and application of oncolytic virus
JP2021526387A (ja) 抗原的にステルス化された腫瘍溶解性ウイルス
Chung et al. Myristylation and polylysine-mediated activation of the protein kinase domain of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10)
US5843405A (en) Epstein-Barr virus peptides and antibodies against these peptides
Wang et al. Herpes simplex virus type 2 glycoprotein E is required for efficient virus spread from epithelial cells to neurons and for targeting viral proteins from the neuron cell body into axons
CN121443325A (zh) 激动剂胞外囊泡
Derbigny et al. The EICP22 protein of equine herpesvirus 1 physically interacts with the immediate-early protein and with itself to form dimers and higher-order complexes